The field of gastroenterology has recently seen a surge in wearable technology to monitor physical activity,sleep quality,pain,and even gut activity.The past decade has seen the emergence of wearable devices including...The field of gastroenterology has recently seen a surge in wearable technology to monitor physical activity,sleep quality,pain,and even gut activity.The past decade has seen the emergence of wearable devices including Fitbit,Apple Watch,AbStats,and ingestible sensors.In this review,we discuss current and future devices designed to measure sweat biomarkers,steps taken,sleep efficiency,gastric electrical activity,stomach pH,and intestinal contents.We also summarize several clinical studies to better understand wearable devices so that we may assess their potential benefit in improving healthcare while also weighing the challenges that must be addressed.展开更多
As the population across the globe continues to dramatically increase,the prevalence of cognitive impairment and dementia will inevitably increase as well,placing increasing burden on families and health care systems....As the population across the globe continues to dramatically increase,the prevalence of cognitive impairment and dementia will inevitably increase as well,placing increasing burden on families and health care systems.Technological advancements over the past decade provide potential benefit in not only relieving caregiver burden of caring for a loved one with dementia,but also enables individuals with dementia to age in place.Technological devices have served to improve functioning,tracking and mobility.Similarly,smartphones,tablets and the ubiquitous world wide web have facilitated the dissemination of health information to previously hard to reach populations largely through use of various social media platforms.In this review,we discuss the current and future uses of technology via devices and social media to promote healthy aging in individuals with dementia,and also limitations and challenges to consider in the future.展开更多
With the Food and Drug Administration designation in 2017 of 3,4-methylenedioxymethamphetamine(MDMA)as a breakthrough therapy in post-traumatic stress disorder and psilocybin in treatment-resistant depression,psychede...With the Food and Drug Administration designation in 2017 of 3,4-methylenedioxymethamphetamine(MDMA)as a breakthrough therapy in post-traumatic stress disorder and psilocybin in treatment-resistant depression,psychedelic drugs have continued to garner the attention of researchers and clinicians for their promise of unmatched,rapid improvement in a multitude of psychiatric conditions.Classic psychedelic drugs including psilocybin,lysergic acid diethylamide,and ayahuasca,as well as non-classic drugs such as MDMA and ketamine,are currently being investigated for a potential therapeutic role in trauma,depressive disorders,and other psychopathologies.However,psilocybin and MDMA each have a functional profile well-suited for integration with psychotherapy.The present review focuses on psilocybin and MDMA in psychedelic-assisted therapy(PAT),as these studies compose most of the literature pool.In this review,we discuss the current and future uses of psychedelic drugs,with an emphasis on the role of MDMA and psilocybin in PAT in the setting of trauma and related comorbidities on the efficacy of psychedelic drugs across multiple psychiatric disorders.The article concludes with thoughts for future research,such as incorporating wearables and standardization of symptom scales,therapy styles,and assessment of adverse drug reactions.展开更多
文摘The field of gastroenterology has recently seen a surge in wearable technology to monitor physical activity,sleep quality,pain,and even gut activity.The past decade has seen the emergence of wearable devices including Fitbit,Apple Watch,AbStats,and ingestible sensors.In this review,we discuss current and future devices designed to measure sweat biomarkers,steps taken,sleep efficiency,gastric electrical activity,stomach pH,and intestinal contents.We also summarize several clinical studies to better understand wearable devices so that we may assess their potential benefit in improving healthcare while also weighing the challenges that must be addressed.
文摘As the population across the globe continues to dramatically increase,the prevalence of cognitive impairment and dementia will inevitably increase as well,placing increasing burden on families and health care systems.Technological advancements over the past decade provide potential benefit in not only relieving caregiver burden of caring for a loved one with dementia,but also enables individuals with dementia to age in place.Technological devices have served to improve functioning,tracking and mobility.Similarly,smartphones,tablets and the ubiquitous world wide web have facilitated the dissemination of health information to previously hard to reach populations largely through use of various social media platforms.In this review,we discuss the current and future uses of technology via devices and social media to promote healthy aging in individuals with dementia,and also limitations and challenges to consider in the future.
文摘With the Food and Drug Administration designation in 2017 of 3,4-methylenedioxymethamphetamine(MDMA)as a breakthrough therapy in post-traumatic stress disorder and psilocybin in treatment-resistant depression,psychedelic drugs have continued to garner the attention of researchers and clinicians for their promise of unmatched,rapid improvement in a multitude of psychiatric conditions.Classic psychedelic drugs including psilocybin,lysergic acid diethylamide,and ayahuasca,as well as non-classic drugs such as MDMA and ketamine,are currently being investigated for a potential therapeutic role in trauma,depressive disorders,and other psychopathologies.However,psilocybin and MDMA each have a functional profile well-suited for integration with psychotherapy.The present review focuses on psilocybin and MDMA in psychedelic-assisted therapy(PAT),as these studies compose most of the literature pool.In this review,we discuss the current and future uses of psychedelic drugs,with an emphasis on the role of MDMA and psilocybin in PAT in the setting of trauma and related comorbidities on the efficacy of psychedelic drugs across multiple psychiatric disorders.The article concludes with thoughts for future research,such as incorporating wearables and standardization of symptom scales,therapy styles,and assessment of adverse drug reactions.
